New Post Hoc Phase 3 Data Analysis Shows AJOVY® (fremanezumab) Reduced Migraine Attacks in Adults with Migraine and Co-morbid Obesity AJOVY® (fremanezumab) efficacy and safety demonstrated in migraine patients with…
Content Section: News Posts
…2021. Available at: Dismissed-for-too-long_Recommendations-to-improve-migraine-care-in-the-UK.pdf. Accessed: May 2023 [iii] WHO. Headache disorders. Headache disorders (who.int) Accessed: May 2023 [iv] The Migraine Trust. What is Migraine? Available at: https://migrainetrust.org/understand-migraine/what-ismigraine/#page-section-1 Accessed: May 2023…
Content Section: News Posts
…medications used for prevention The trial met its primary and secondary endpoints with results showcasing a significant reduction in mean monthly migraine days for those with episodic migraine taking atogepant…
Content Section: News Posts
…for a specific gene for migraine. Migraine has a genetic cause but so far the gene has only been identified in the rare familial hemiplegic migraine. Dr Irene Tracey from…
Content Section: Conference Reports
…since clinical symptoms often return or worsen before the next dose of many preventive migraine medications is due. Migraine can be a debilitating disease, so evaluating migraine days throughout a…
Content Section: News Posts
New AJOVY® (fremanezumab) migraine prevention data presented at the EAN 4th interim analysis of PEARL real world migraine prevention study presented at 10th European Association of Neurology (EAN) congress in…
Content Section: News Posts
…and sound, and changes in vision.3 Episodic migraine is characterised by those with migraine who have to 14 headache days per month, while chronic migraine is characterised by 15 or…
Content Section: News Posts
…— to treat an acute migraine headache, to prevent migraine if taken chronically, and now we see that they can also stop a migraine from developing if taken during the…
Content Section: News Posts
…for migraine and other idiopathic pain conditions, announced the inclusion of its Nerivio Remote Electrical Neuromodulation (REN) wearable, for use in the acute and preventive treatment of migraine, under a…
Content Section: News Posts
© 2024 ACNR. Published by Whitehouse Publishing. Read our Privacy and Cookie Policy. Website by Sugar Web.
Sign up to receive our email newsletter with links to the latest content. ACNR is free, thanks to the support of advertisers. The editorial content is peer reviewed and remains completely independent unless clearly specified.
For UK-based specialists, sign up for our journal mailing list.
URL here
You are now leaving the ACNR website, please click the "Continue" button below. If you do not wish to leave, please close this pop-up.
